The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2017:
51 negotiations are currently underway with 6 new files added since the last update of August 31, 2017:
Fibristal (ulipristal acetate): Used to treat uterine fibroids (2nd cycle pre-surgery)
Glatect ... Read More
11
Oct2017
11
Sep2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2017:
47 negotiations are currently underway with 6 new files added since the last update of July 31, 2017:
Brilinta (ticagrelor): Used with ASA to prevent atherothrombotic events with history ... Read More
09
Aug2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2017:
46 negotiations are currently underway with 7 new files added since the last update of June 30, 2017:
Cinqair (reslizumab): Used to treat severe eosinophilic asthma
Giotrif (afatinib): Used to ... Read More
11
Jul2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2017:
42 negotiations are currently underway with 6 new files added since the last update of May 31, 2017:
Caprelsa (vandetanib): Used to treat medullary thyroid cancer
Kyprolis (carfilzomib): Used to ... Read More
15
Jun2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of May 31, 2017:
43 negotiations are currently underway with 9 new files added since the last update of April 30, 2017:
Brivlera (brivarcetam): Used to treat partial-onset seizures
Butrans (buprenorphine): Used to treat ... Read More
16
May2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017:
38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017:
Cosentyx (secukinumab): Use to treat psoriatic arthritis
Cosentyx (secukinumab): Used to treat ... Read More
13
Apr2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017:
30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017:
Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma
Campral ... Read More
16
Mar2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017:
33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017:
Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein ... Read More
28
Nov2016
Effective November 30, 2016, the Ontario Public Drug Programs will begin funding INFLECTRA™ (infliximab) as a limited use benefit for the following new indications:
LU Code 477 - For the treatment of ulcerative colitis in patients who meet clinical criteria.
LU Code 478 - For the treatment of moderate to severe Crohn’s ... Read More
13
Oct2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2016:
37 negotiations are currently underway with no new files added since the last update of August 31, 2016.
118 joint negotiations have been completed with 4 files successfully negotiated ... Read More